公开(公告)号：US11851467B2

公开(公告)日：2023-12-26

申请号：US18080275

申请日：2022-12-13

申请人： Cue Biopharma, Inc.

发明人： Ronald D. Seidel, III ,  Rodolfo J. Chaparro

IPC分类号： A61K9/00 ,  A61P21/00 ,  C07K14/005 ,  C07K14/55 ,  A61K35/17 ,  C07K14/47 ,  C07K14/74 ,  G01N33/50 ,  A61K38/00 ,  A61K39/00

CPC分类号： C07K14/55 ,  A61K9/0019 ,  A61K35/17 ,  C07K14/005 ,  C07K14/4748 ,  C07K14/70539 ,  G01N33/5008 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2319/30

摘要： The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

公开(公告)号：US20230331800A1

公开(公告)日：2023-10-19

申请号：US18314205

申请日：2023-05-09

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi WU ,  Tong ZHANG ,  Maria del Pilar MOLINA-PORTELA ,  Eric SMITH ,  Chia-Yang LIN ,  Thomas Craig MEAGHER

IPC分类号： C07K14/55 ,  A61K47/68 ,  A61P35/00 ,  C07K14/715 ,  A61K35/17 ,  C07K14/74 ,  A61K38/20 ,  C07K14/725 ,  C07K14/705

CPC分类号： C07K14/55 ,  A61K47/6849 ,  A61P35/00 ,  C07K14/7155 ,  A61K35/17 ,  C07K14/70539 ,  A61K38/2013 ,  C07K14/7051 ,  C07K14/70517 ,  A61K38/00

摘要： The present disclosure relates to IL2 agonists with improved therapeutic profiles.

公开(公告)号：US11786552B2

公开(公告)日：2023-10-17

申请号：US16798465

申请日：2020-02-24

申请人： HANGZHOU CONVERD CO., LTD. ,  Yafei Hou

发明人： Yafei Hou ,  Fang Hu ,  Jipo Sheng ,  Xiankui Tan ,  Can Chen

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K35/768 ,  A61K38/28 ,  A61K38/17 ,  A61P35/00 ,  C07K14/725 ,  C07K14/74 ,  C12N7/00

CPC分类号： A61K35/17 ,  A61K35/768 ,  A61K38/1774 ,  A61K38/28 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C12N7/00

摘要： A therapeutic agent and method of administering the therapeutic agent for the treatment of tumors and/or cancers of a subject, the therapeutic agent comprising a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide comprising one or more antigenic epitope peptides and/or encoding a MHC protein; a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro; wherein the nucleic acid when administered to the subject as part of the pharmaceutical composition causes the tumor cells and/or cancer cells of the subject to express the one or more antigenic epitope peptides to elicit an immune response of the immune cells.

公开(公告)号：US20230322865A1

公开(公告)日：2023-10-12

申请号：US18164313

申请日：2023-02-03

申请人： Eberhard Karls Universität Tübingen Medizinische Fakultät

发明人： Juliane Walz ,  Annika Nelde ,  Hans-Georg Rammensee ,  Tatjana Bilich

IPC分类号： C07K14/005 ,  C07K14/725 ,  C07K14/74 ,  A61P31/14 ,  A61K39/215 ,  A61K39/39

CPC分类号： C07K14/005 ,  C07K14/7051 ,  C07K14/70539 ,  A61P31/14 ,  A61K39/215 ,  A61K39/39 ,  C12N2770/20034 ,  C12N2770/20022 ,  C12N2770/20071 ,  A61K2039/55516

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of an infection by SARS-CoV-2 (COVID-19). The present invention furthermore relates to SARS-CoV-2-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-SARS-CoV-2 immune responses, or to stimulate T-cells ex vivo and transfer them into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11779607B2

公开(公告)日：2023-10-10

申请号：US17827142

申请日：2022-05-27

申请人： Avotres, Inc.

发明人： Hong Jiang

IPC分类号： A61K35/17 ,  A61P37/02 ,  G01N33/50 ,  C12N5/0783 ,  C07K14/74 ,  C12N5/0784 ,  A61K31/10 ,  A61K35/15 ,  A61K38/17 ,  A61K38/38 ,  A61P37/04 ,  A61P17/06 ,  A61P25/28 ,  A61P37/06 ,  A61P19/02 ,  A61K47/20 ,  A61K47/42

CPC分类号： A61K35/17 ,  A61K31/10 ,  A61K35/15 ,  A61K38/1709 ,  A61K38/38 ,  A61K47/20 ,  A61K47/42 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/70539 ,  C12N5/0637 ,  C12N5/0639 ,  G01N33/505 ,  C12N2501/22 ,  C12N2501/2304

摘要： The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

公开(公告)号：US20230303656A1

公开(公告)日：2023-09-28

申请号：US18333942

申请日：2023-06-13

申请人： BioNTech Cell & Gene Therapies GmbH ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

发明人： Ugur Sahin ,  Ozlem Tureci ,  Petra Oehm ,  Tana Omokoko ,  Andrea Breitkreuz ,  Karolina Anna Mroz ,  Lisa Hebich

IPC分类号： C07K14/725 ,  C07K7/06 ,  A61K39/00 ,  C07K14/705 ,  C07K14/74 ,  C07K16/28

CPC分类号： C07K14/7051 ,  C07K7/06 ,  A61K39/0011 ,  C07K14/705 ,  C07K14/70521 ,  C07K14/70539 ,  C07K16/28 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/575 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/30

摘要： The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

公开(公告)号：US20230295563A1

公开(公告)日：2023-09-21

申请号：US17971071

申请日：2022-10-21

申请人： Sangamo Therapeutics, Inc.

发明人： Anthony Conway ,  Sumiti Jain ,  Gary K. Lee ,  David Paschon ,  Edward J. Rebar ,  Lei Zhang

IPC分类号： C12N5/0783 ,  C12N9/22 ,  A61P37/06 ,  A61P35/00 ,  C07K14/725 ,  A61K48/00 ,  C12N15/85 ,  C12N15/90 ,  C07K14/74

CPC分类号： C12N5/0636 ,  A61K48/0066 ,  A61P35/00 ,  A61P37/06 ,  C07K14/7051 ,  C12N9/22 ,  C12N15/907 ,  C12N15/8509 ,  A61K48/005 ,  C07K14/70539 ,  C12N2015/8518 ,  C12N2501/515 ,  C12N2510/00 ,  C12N2750/14143

摘要： Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.

公开(公告)号：US20230287347A1

公开(公告)日：2023-09-14

申请号：US18295631

申请日：2023-04-04

申请人： THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Tai Gyu KIM ,  Hyun Jung SOHN ,  Su Eon KIM

IPC分类号： C12N5/0783 ,  C07K14/705 ,  C07K14/735 ,  C07K14/74 ,  C07K14/715

CPC分类号： C12N5/0636 ,  C07K14/70532 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/70596 ,  C07K14/7151 ,  C12N5/0638 ,  C12N2501/25 ,  C12N2501/51 ,  C12N2501/599

摘要： The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.

公开(公告)号：US20230265157A1

公开(公告)日：2023-08-24

申请号：US18012573

申请日：2021-06-23

申请人： Repertoire Immune Medicines, Inc.

发明人： Joanna Swain ,  Michael Birnbaum

IPC分类号： C07K14/74 ,  C07K14/005 ,  C07K14/47 ,  C07K14/36 ,  G01N33/569

CPC分类号： C07K14/70539 ,  C07K14/005 ,  C07K14/4703 ,  C07K14/36 ,  G01N33/56977 ,  C07K2319/03 ,  C07K2319/02

摘要： MHC multimer expression constructs are provided that contiguously encode an MHC-binding peptide, MHC molecule chains and a multimerization domain in the construct such that expression in a host cell results in production of peptide-loaded MHC (pMHC) multimers by the host cell. The multimers can further comprise oligonucleotide barcodes. Peptide exchange can be performed with a plurality of pMHC multimers to create pMHC multimer libraries. Methods of making and using the pMHC multimers and libraries are also provided. Peptide-loaded MHC Class I and MHC Class II multimers, and libraries thereof, are provided.

公开(公告)号：US11732020B2

公开(公告)日：2023-08-22

申请号：US16309902

申请日：2017-06-16

申请人： MEDIGENE IMMUNOTHERAPIES GMBH

发明人： Christian Ellinger ,  Carina Wehner ,  Manon Weis ,  Susanne Wilde ,  Dolores Schendel

IPC分类号： C07K14/725 ,  C07K14/735 ,  C07K14/74 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  A61P35/00 ,  A61K35/17

CPC分类号： C07K14/7051 ,  A61K35/17 ,  A61K39/00119 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/3053 ,  A61K2039/5154 ,  C07K2317/34 ,  C07K2317/73

摘要： The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.